Medy-Tox, Inc. engages in the manufacture and sale of biopharmaceutical products. Its products include botulinum toxin, hyaluronic acid filler, medical devices, toxin detection kit and antitoxin therapeutics. The company was founded on May 2, 2000 and is headquartered in Cheongwon-gun, South Korea.

Hunter-Fleming Ltd. dvelops pharmaceutical products. The company was founded by James R. Murray, John S. Fox and Ernst Wülfert in February 1999 and is headquartered in Brixham, the United Kingdom.

Zhejiang Xianju Pharmaceutical Co., Ltd (仙琚制药) is a Chinese company manufacturing steroid drug products, steroid hormone medicines, and medicines for birth control. The company’s main business is focused on the development, production, and sale of raw materials and preparation of pharmaceutics for steroid drugs. Its products are based on three categories: corticosteroid drugs, sex hormone drugs (gynecological and birth control medication), and anesthesia and muscle relaxation drugs. These categories consist of more than 200 varieties of drugs. Currently, all the products of the company have passed the authentication of GMP. It has built a long-term partnership with more than twenty famous scientific research institutes and universities in China such as Shanghai Institute of Organic Chemistry and Chinese Pharmaceutical University. Xianju Pharmaceutical was established in 1972.

Shanxi Zhendong Pharmaceutical Co., Ltd. engages in the research and development, manufacture and distribution of Chinese traditional medicines and western medicines. Its products include Yanshu injection, Norfloxacin, Shuxuening injection, Guanxinning injection, Amoxicillin Sodium for injection, Cefathiamidine for injection and Riboflavin Sodium Phosphate for injection. The company was founded on November 22, 1993 and is headquartered in Changzhi, China.

Hubei Wudang Antai Pharmaceutical Co., Ltd., established on 2021-01-19, Business scope includes licensed projects:Drug import and export;Import and export;Technology Import and Export;Import and export agency;pharmaceutical production(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)General project:Manufacturing of basic chemical raw materials(Manufacture of licensed chemicals free of hazardous chemicals);Chemical product production(No licensed chemical products);Chemical product sales(No licensed chemical products)(Except for licensed business,Can independently operate projects that are not prohibited or restricted by laws and regulations)

Xianju (Jiaxing) Pharmaceutical Technology Co., Ltd., established on 2020-10-16, Business scope includes licensed projects:Inspection and testing service;Technology Import and Export;Import and export;Import and export agency(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results).General project:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Medical Research and Experimental Development;Engineering and Technology Research and Experimental Development;Specialty Chemicals Sales(Free of Hazardous Chemicals);Chemical product sales(No licensed chemical products)(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).

Beijing Huarui Dingxin Technology Co., Ltd., established on 1999-01-27, Business scope includes general items:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Socioeconomic Advisory Services;Labor service(Does not include labor dispatch).(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)licensed items:Pharmaceutical commissioned production;Inspection and testing service.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)(Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

Deargen, Inc. is a company headquartered in Daejeon, the South Korea. The firm operates as an artificial intelligence-based drug development platform company. It was founded in 2016. Kil-Soo Kang is currently the CEO of the firm.\nThe company says this about itself: Established in December 2016, Deargen (CEO: Kilsoo Kang) is an AI-based drug discovery and development company. In February 2020, the company released study results on predicting the development of COVID-19 treatments. Candidate compounds for treating COVID-19 predicted by Deargen include remdesivir, which was first approved as an emergency therapy. The company conducts research on and owns core AI technologies in-silico, such as 'prediction of bio-markers', 'selection of disease targets', and 'extraction of candidate substances for new drugs', utilizing techniques of meta analysis of genome big data and its unique AI technologies. Building on these outcomes, the company is developing new drugs in collaboration with multiple pharmaceutical companies and research institutions, demonstrating its outstanding technology capabilities as being named as top awardees at the ILSVRC, a world-prominent deep-learning competition, and Dream Challenge, an international AI-based new drug development competition.

F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Jiangxi Junye Biopharmaceutical Co., Ltd., established on 2012-02-24, The business scope includes the manufacture of pharmaceutical intermediate products,Sales;API manufacturing,Sales;Chemical raw materials(except dangerous goods)and intermediate development,manufacture,Sales;Goods and technology import and export business.

As of January 6, 2009, Genelabs Technologies Inc. was acquired by SmithKline Beecham Corporation. Genelabs Technologies, Inc., a biopharmaceutical company, engages in the discovery and development of infectious disease therapies to improve human health. The company's product pipeline consists of infectious disease projects focusing on Hepatitis C virus infection; and late-stage clinical assets, including an investigational vaccine for hepatitis E virus that is being developed by GlaxoSmithKline; and Prestara, an investigational drug for systemic lupus erythematosus. It has license and collaboration agreement with the Novartis Institutes for BioMedical Research for HCV polymerase non-nucleoside discovery research. Genelabs Technologies also has a collaborative research agreement with the National Health Research Institutes and Genovate Biotechnology Co., Ltd. to discover and develop compounds that target the hepatitis C virus. The company was founded in 1983 and is headquartered in Redwood City, California.

Zhejiang Donghui Pharmaceutical Co., Ltd., established on 2004-07-21, Business scope includes raw materials(Free of hazardous chemicals and precursor chemicals),Manufacturing of organic intermediates;Import and export,Technology Import and Export.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Hubei Minsheng Biopharmaceutical Co., Ltd., established on 2000-10-17, Diene,Worth,oxygen bridge,Monoene and its by-product production and sales;Research and development of steroid hormone intermediates;Sales of building materials;Foreign trade operation(Involved in licensing projects,It should be operated after obtaining the permission of the relevant department)**

Hubei Danjiangkou Kaitai Hormone Co., Ltd., established on 2003-05-12, The business scope includes hormone intermediates and raw materials(Does not contain national restricted varieties)Production,Sales;Chemical raw material sales(Hazardous and highly toxic chemicals are excluded);Manage the export business of the company's self-produced products and technologies,Raw and auxiliary materials required for the production of the enterprise(Except for commodities and technologies that are restricted by the state to operate by the company and prohibited by the state from export);Operating incoming material processing and"Three to one make up"business(Operating under the import and export business license);General cargo transportation.(Involved in licensing projects,It should be operated after obtaining the permission of the relevant department)***

CNPEM is a social organization supervised by the Ministry of Science, Technology, and Innovation (MCTI).

Laboratorios Andrómaco SA is a pharmaceutical company. It is engaged in the production and marketing of pharmaceutical products and diagnostics. The company was founded in 1942 and is headquartered in Peñalolén, Chile.

Hubei Biopesticide Engineering Research Center is a Chinese private company with domestic subsidiaries, that operates as engineering research center.

Fuan Pharmaceutical Group Chongqing Bosheng Pharmaceutical Co., Ltd., established on 2016-09-01, The scope of business includes the production of hazardous chemicals(Engage in business according to the approved items and time limit of the license);research and development,Production,selling medicines;Research,Develop fine chemical products,specialty chemicals;Production,Sales of chemical products;medicine,Chemical Products(The above business scope does not include hazardous chemicals other than those approved by the license)technology transfer;Import and export.(Items subject to approval according to law in the above scope,Business activities can only be carried out after approval by relevant departments)**

Chongqing Kangle Pharmaceutical Co., Ltd., established on 1988-01-14, Business scope includes licensed projects:Production,Sales(Limited to the company's self-produced drugs):API(Cilostazol,Chloroquine Phosphate,piperaquine phosphate,Amodiaquine Hydrochloride,Hydroxychloroquine Sulfate,Tigecycline(for export only);Production,Sales:Pharmaceutical Intermediates;Import and export of goods and technology.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)General project:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)